JP4874234B2 - 非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用 - Google Patents

非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用 Download PDF

Info

Publication number
JP4874234B2
JP4874234B2 JP2007506605A JP2007506605A JP4874234B2 JP 4874234 B2 JP4874234 B2 JP 4874234B2 JP 2007506605 A JP2007506605 A JP 2007506605A JP 2007506605 A JP2007506605 A JP 2007506605A JP 4874234 B2 JP4874234 B2 JP 4874234B2
Authority
JP
Japan
Prior art keywords
anln
rhoa
cell
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007506605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510126A (ja
JP2008510126A5 (cg-RX-API-DMAC7.html
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2008510126A publication Critical patent/JP2008510126A/ja
Publication of JP2008510126A5 publication Critical patent/JP2008510126A5/ja
Application granted granted Critical
Publication of JP4874234B2 publication Critical patent/JP4874234B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007506605A 2004-08-10 2005-08-09 非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用 Expired - Fee Related JP4874234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
US60/600,561 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (3)

Publication Number Publication Date
JP2008510126A JP2008510126A (ja) 2008-04-03
JP2008510126A5 JP2008510126A5 (cg-RX-API-DMAC7.html) 2008-09-25
JP4874234B2 true JP4874234B2 (ja) 2012-02-15

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506605A Expired - Fee Related JP4874234B2 (ja) 2004-08-10 2005-08-09 非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用

Country Status (6)

Country Link
US (1) US20090297500A1 (cg-RX-API-DMAC7.html)
EP (1) EP1787122B1 (cg-RX-API-DMAC7.html)
JP (1) JP4874234B2 (cg-RX-API-DMAC7.html)
AT (1) ATE483979T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005024021D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006016697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
AU2007322206A1 (en) * 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
EP2142648A4 (en) * 2007-03-30 2011-09-14 Oncotherapy Science Inc SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP6127972B2 (ja) 2011-09-09 2017-05-17 コニカミノルタ株式会社 組織染色方法
ES2674318T3 (es) * 2011-10-24 2018-06-28 Somalogic, Inc. Biomarcadores de cáncer de pulmón y usos de los mismos
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2522299A1 (en) * 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods

Also Published As

Publication number Publication date
JP2008510126A (ja) 2008-04-03
EP1787122B1 (en) 2010-10-06
EP1787122A1 (en) 2007-05-23
WO2006016697A1 (en) 2006-02-16
US20090297500A1 (en) 2009-12-03
ATE483979T1 (de) 2010-10-15
DE602005024021D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
JP4874234B2 (ja) 非小細胞肺癌関連遺伝子ＡＮＬＮ、およびそのＲｈｏＡとの相互作用
Kim et al. DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation
US20100135910A1 (en) Modulation of Anergy and Methods for Isolating Anergy-Modulating Compounds
KR20100075857A (ko) 폐암의 치료 및 진단의 표적유전자인 ｅｂｉ３，ｄｌｘ５，ｎｐｔｘ１ 및 ｃｄｋｎ
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2010501172A (ja) 肺癌に対する予後マーカーおよび治療標的
US20100144543A1 (en) Epigenetic silencing of tumor suppressor genes
WO1999004238A2 (en) Reagents and methods for diagnosis and prognosis of proliferative disorders
KR101549245B1 (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
JP2010501827A (ja) Ｍｐｈｏｓｐｈ１とｐｒｃ１の結合を阻害する作用物質のスクリーニング方法
KR20100082161A (ko) ＲＯＲα를 이용한 항암제 스크리닝 방법
KR101943157B1 (ko) 유방암 예후 예측용 바이오마커
KR20110067107A (ko) 종양 마커 및 암에 대한 치료적 표적으로서 ｔｂｃ１ｄ７
Winter et al. Co-deletion of ATAD1 with PTEN primes cells for BIM-mediated apoptosis
US20250320501A1 (en) Palmitoylation of the alternative amino terminus of the btk-c isoform controls subcellular distribution and signaling
KR20100128326A (ko) 암 치료 및 진단을 위한 표적 유전자인 ｃ2ｏｒｆ18
KR102258977B1 (ko) CDK1-Cyclin B1의 결합 억제제를 이용한 암 치료물질의 스크리닝 방법
JP4256169B2 (ja) Ｔｕｃａｎを用いて癌患者の予後を決定するための方法
KR102138229B1 (ko) CDK1-Cyclin B1의 결합 억제제를 이용한 암 치료물질의 스크리닝 방법
Prabhu Investigating the Therapeutic and Biological Impact of MNK1/2 Kinases
US20070254830A1 (en) Interaction of Colon Cancer Related Gene C200RF20 With P120
Loftus et al. Research Article A Novel Interaction between Pyk2 and MAP4K4 Is Integrated with Glioma Cell Migration
WO2001040293A2 (en) Method of modulating proapoptotic and antiapoptotic pathways in cells
KR20140018411A (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees